We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current BIM market cap is 13.52B. The company's latest EPS is EUR 3.6644 and P/E is 31.30.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 3.09B | 3.38B | 3.53B | 3.63B | 3.9B |
| Operating Income | 552.7M | 784.3M | 587.3M | 438.7M | 588.8M |
| Net Income | 404.4M | 601.1M | 452.4M | 357.6M | 432.2M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 3.93B | 4.61B | 5.19B | 5.26B | 5.77B |
| Total Liabilities | 1.45B | 1.44B | 1.54B | 1.51B | 1.56B |
| Total Equity | 2.48B | 3.16B | 3.64B | 3.75B | 4.21B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 582.8M | 824.7M | 475.1M | 445.5M | 667.3M |
| Investing | -265.2M | -307.3M | -528.1M | -488.8M | -359.8M |
| Financing | -176.2M | -140.6M | -244.3M | -122.3M | -212.6M |
| Market Cap | 13.52B |
| Price to Earnings Ratio | 31.30 |
| Price to Sales Ratio | 3.47 |
| Price to Cash Ratio | 30.08 |
| Price to Book Ratio | 3.21 |
| Dividend Yield | 0.79% |
| Shares Outstanding | 117.95M |
| Average Volume (1 week) | 206.39k |
| Average Volume (1 Month) | 156.81k |
| 52 Week Change | 9.56% |
| 52 Week High | 120.00 |
| 52 Week Low | 88.25 |
| Spread (Intraday) | 0.2 (0.17%) |
| Company Name | Biomerieux |
| Address |
chemin de l'orme lyon, rhone 69280 |
| Website | https://www.biomerieux.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
